Loading page…

Shukra Pharmaceuticals Ltd (SHUKRAPHAR) · mywealthgrid

About

Shukra Pharmaceuticals operates in India's pharmaceutical sector as a small-cap player (₹1,813.78 Cr market cap). The company has seen exceptional share returns of 116.75% over the past year, and quarterly revenues have ranged from ₹3.18 Cr to ₹24.64 Cr over the past 24 months, indicating operational volatility.

Face value: ₹1

Market cap

₹2,706 Cr

P/E

282.6×

P/B

43.1×

Dividend yield

ROE

15.9%

ROCE

20.9%

Debt / equity

0.07

OPM

39.1%

EPS (TTM)

₹0.2

Book value

₹1.4

52-week high

₹62.4

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Quarterly revenue has fluctuated from ₹3.18 Cr (June 2024) to ₹24.64 Cr (September 2023); verify whether recent growth is sustainable or driven by one-time orders or customer concentration.
Operating margins swung from 1.69% (June 2023) to 55.16% (March 2025); clarify the drivers of this variability and whether current high margins are achievable at scale.
PE ratio of 189.43 leaves little room for near-term earnings misses; assess growth visibility and the risk of multiple compression if expansion slows.
No FII presence and minimal DII (0.11%) suggest limited institutional validation; verify whether this reflects size, sector headwinds, or governance concerns.

Generated analysis · source review pending

Growth drivers

Recent operating margins of 55.16% (March 2025) and 37.13% (December 2024) demonstrate profitability; verify sustainability of these margins as production scales.
Debt-to-equity ratio of 0.07 provides financial flexibility for growth investments, capex, or M&A without immediate dilution.
Quarterly revenue expanded from ₹3.18 Cr (June 2024) to ₹13.27 Cr (March 2025); verify whether this growth reflects new products, customer wins, or geographies and whether the trajectory can be sustained.

Generated analysis · source review pending

₹61.8+79.2%1Y

Beta

0.04

Damps index moves

Volatility (1y)

57.3%

Annualised, daily returns

RSI (14)

72.5

Overbought territory

Rel. strength (1y)

74%

Ahead of the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Strong return on equity of 27.3% (3-yr avg)
+High return on capital employed of 26.7%
+Healthy operating margin of 39.1%
+Profit CAGR of 175.8% over the last 5 years
+Revenue CAGR of 25.5% over the last 5 years
+Almost debt-free (debt/equity 0.1)
+Comfortable interest coverage of 23.6×
+Outperformed the universe by 74% over 1 year

Cons

−Expensive at 282.6× trailing earnings
−Trading at 43.1× book value
−Low dividend payout of 4.6% of profit

Research score

Structured signal from quality, growth, valuation and momentum.

67/100

Business quality

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	5	5	5	6	10	11	20	59	75	33
COGS	-2	-1	-1	-1	-3	3	10	45	-44	-8
Gross profit	—	—	—	—	—	8	10	14	—	—
	5	5	5	5	13	7	7	8	100	28
Operating profit (EBITDA)	1	1	2	2	0	1	3	5	19	13
OPM %	28.6%	28.6%	29.1%	30.6%	1.3%	12.9%	14.1%	9.1%	26%	39.1%
Depreciation	1	0	1	1	1	1	2	2	2	3
Interest	—	—	—	—	—	0	0	0	0	1
	0	—	0	0	—	0	0	1	3	4
Profit before tax	0	1	1	1	0	0	1	4	20	13
Tax	—	0	-0	0	—	-0	0	0	1	4
Tax %	—	35.5%	-1.1%	61.8%	—	-90%	26.5%	0.9%	6.8%	28.2%
	0	1	1	0	0	0	1	4	19	10
PAT margin %	4.6%	13.7%	16.6%	5.1%	0.6%	1.7%	3.7%	7.5%	24.9%	29.4%
EPS (₹)	0.1	0.5	—	—	0.4	1.2	4.8	26.2	14.3	1.1
EPS adjusted (₹)	—	—	—	—	—	0	0.1	0.3	0.4	0.2
	0%	0%	—	—	0%	0%	10.4%	1.9%	7%	0.9%
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity capital	2	2	4	11	44
Reserves	14	15	21	47	19
Minority interest	—	—	0	—	—
	10	3	5	3	4
	10	15	45	17	20
Total equity & liabilities	36	35	75	78	87
	18	18	20	20	19
CWIP	2	2	2	2	2
Investments	0	0	0	—	—
	16	16	53	56	65
Total assets	36	35	75	78	87

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	1	8	3	-5	8
	-2	-2	-4	-1	-1
	2	-7	5	12	-5
Net cash flow	0	-0	4	6	2
Free cash flow	-1	6	-1	-5	8
CFO / Operating profit %	37.5%	269.2%	59.1%	-26.8%	62.2%

Compounded sales growth

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Margins
Gross margin %	—	—	—	75.3%	49.5%	23%	—	—
EBITDA margin %	29.1%	30.6%	1.3%	12.9%	14.1%	9.1%	26%	39.1%
EBIT margin %	15.3%	13.6%	-12.8%	-0.3%	6%	6%	23.3%	29.8%
PAT margin %	16.6%	5.1%	0.6%	1.7%	3.7%	7.5%	24.9%	29.4%
Working capital
Receivable days	—	—	—	318	132	187	120	98
Inventory days	—	—	—	221	139	25	15	183
Payable days	—	—	—	702	303	276	48	169
NWC days	—	—	—	-163	-32	-63	87	112
Leverage
Current ratio	—	—	—	2.28	1.27	1.25	3.97	3.79
Debt to EBITDA	—	—	—	6.78	1.17	0.95	0.16	0.33
Debt to equity	—	—	—	0.63	0.21	0.2	0.05	0.07
Interest coverage	—	—	—	10.7	4.5	16.9	69.6	23.6
Asset turnover	—	—	—	0.31	0.58	0.78	0.96	0.38
Return ratios
Return on assets %	—	—	—	0.5%	2.1%	5.9%	23.8%	11%
Return on capital employed %	—	—	—	1.1%	5.1%	17.1%	42%	20.9%
Return on equity %	—	—	—	1.2%	4.6%	17.4%	32.2%	15.2%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	50.9%	50.96%	50.96%	50.96%	50.96%	50.96%	50.96%	50.96%	50.96%	50.96%	50.96%	50.96%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	48.99%	48.93%	48.93%	48.93%	48.93%	48.93%	48.93%	48.93%	48.93%	48.93%	48.93%	48.93%
No. of shareholders	—	—	—	—	—	—	—	—	21,441	25,649	27,173	28,384

Promoter holding up 0.06 percentage points since Sep 2023.

Mr. DAKSHESH RAMESHCHANDRA SHAHExecutive Director-Chairperson related to Promoter
Ms. PAYAL SUJAY MEHTAExecutive Director
Ms. SHEETAL SHAHNon-Executive - Non Independent Director
Ms. RITU KAPOORNon-Executive - Independent Director
Ms. ANAR JAYESHBHAI PATELExecutive Director
Mr. JITENDRA SOMCHAND SHAHNon-Executive - Independent Director
Ms. PINKI NIRMAL SAGARNon-Executive - Independent Director
Ms. SONAL DEEPALBHAI GANDHINon-Executive - Independent Director
Ms. SANSKRUTI JAYESHBHAI PATELExecutive Director
Mr. SARJEEVAN SINGHNon-Executive - Independent Director
Mr. DHRUVIN SHAHExecutive Director

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Shukra Pharmaceuticals Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

7

Final dividend21 Sept 2026 · ex-date₹0.01
Final dividend18 Sept 2025 · ex-date₹0.01
Final dividend23 Sept 2024 · ex-date₹1
Final dividend15 Sept 2023 · ex-date₹0.5
Final dividend22 Sept 2022 · ex-date₹0.5
Final dividend19 Sept 2019 · ex-date₹0.5
Dividend dividend31 Aug 2018 · ex-date₹0.5

1

Board meeting to consider results12 Aug 2026

1

Face value ₹10 → ₹121 Mar 2025 · ex-date

1–3 of 4

1 / 2

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

40 announcementsExport CSV

29 Sept 2026, 7:49 pmAGM/EGM

Voting Results With Scrutinizer Report

Postal Ballot PDF

Loading announcements…

Date	Category	Subject	Filing
29 Sept 2026, 7:49 pm	AGM/EGM Postal Ballot	Voting Results With Scrutinizer Report	PDF
29 Sept 2026, 6:42 pm	AGM/EGM AGM	Voting Results And Scrutinizer''s Report	PDF
28 Sept 2026, 2:28 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
22 Sept 2026, 6:26 pm	AGM/EGM Postal Ballot	Corrigendum To Postal Ballot Notice	PDF
5 Sept 2026, 9:37 pm	Others Reg. 34 (1) Annual Report	Reg. 34 (1) Annual Report.	PDF
5 Sept 2026, 9:29 pm	AGM/EGM AGM	AGM NOTICE	PDF
3 Sept 2026, 8:06 pm	AGM/EGM AGM	Update On Date Of AGM	PDF
3 Sept 2026, 12:15 pm	Corp. Action Dividend Updates	Announcement under Regulation 30 (LODR)-Dividend Updates	PDF

Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Compounded sales growth

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

7

1

1

Announcements

No fund holdings on record

Not in the F&O segment

7

1

1

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd

About

Key insights

Key risks

Growth drivers

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Ratios

Ratio timeline

Shareholding

Quarterly record

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Dividends7

Board meetings1

Stock splits1

Announcements

No fund holdings on record

Not in the F&O segment

Dividends7

Board meetings1

Stock splits1

Ratio timeline

Announcements

Annual reports

Quarterly record

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

7

1

1

7

1

1